Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.9%

14 terminated/withdrawn out of 141 trials

Success Rate

89.3%

+2.8% vs industry average

Late-Stage Pipeline

40%

56 trials in Phase 3/4

Results Transparency

42%

49 of 117 completed trials have results

Key Signals

2 recruiting49 with results9 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2

46(32.6%)

N/A

29(20.6%)

Phase 3

28(19.9%)

Phase 4

28(19.9%)

Phase 1

9(6.4%)

Early Phase 1

1(0.7%)

141Total

Phase 2(46)

N/A(29)

Phase 3(28)

Phase 4(28)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (141)

Showing 20 of 141 trials

NCT05204407Not ApplicableCompleted

Luteolin for the Treatment of People With Schizophrenia

Role: collaborator

NCT03794076Phase 1Recruiting

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

Role: collaborator

NCT04211961Phase 2Completed

Scopolamine in Bipolar Depression

Role: collaborator

NCT04887792Phase 1Recruiting

Acetazolamide for Treatment Resistant Schizophrenia

Role: collaborator

NCT01602029Phase 2Completed

Randomized Double Blind Placebo Control Study in Patients with Schizophrenia

Role: collaborator

NCT03437668Phase 2Terminated

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

Role: collaborator

NCT02685748Phase 2Completed

Aspirin in Young Psychotic Patients

Role: collaborator

NCT01479829Phase 4Completed

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Role: collaborator

NCT01573637Phase 3Completed

Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women

Role: collaborator

NCT02796859Phase 1Unknown

Siltuximab in Schizophrenia

Role: collaborator

NCT02800161Phase 3Completed

Trehalose as add-on Therapy in Bipolar Depression

Role: collaborator

NCT02686697Phase 2Completed

Carnosine and Cognitive Training in Schizophrenia

Role: collaborator

NCT02417142Phase 4Completed

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

Role: collaborator

NCT02118610Not ApplicableCompleted

Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

Role: collaborator

NCT00492349Phase 4Completed

Varenicline Adjunctive Treatment in Schizophrenia

Role: collaborator

NCT02082678Phase 4Completed

Ondansetron for Bipolar Disorder and Alcohol Use Disorders

Role: collaborator

NCT02519543Phase 3Completed

Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder

Role: collaborator

NCT00176423Phase 4Completed

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Role: collaborator

NCT00221403Phase 3Completed

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

Role: collaborator

NCT01999309Phase 3Completed

Simvastatin Addition for Patients With Recent-onset Schizophrenia

Role: collaborator